mRNA vaccine Project Launched: A collaborative Effort

In a move to strengthen its biopharmaceutical sector and enhance its response to future pandemics, South Korea is making a ample investment in domestic mRNA vaccine development. EU BIOLOGICS has been selected to spearhead the MRNA Vaccine Development Project, an initiative orchestrated by the Korea Centers for Disease Control and Prevention (KCDC).

The project, officially titled Non-Trial Development of vaccine Development of Colona and Variable Infectious Diseases Based on Domestic MRNA Platform Technology, has the ambitious goal of securing regulatory approval for domestically produced mRNA vaccines. This initiative reflects a growing global trend towards mRNA technology, recognized for its potential in rapidly developing vaccines against emerging infectious diseases.

EU BIOLOGICS leads the Charge

EU BIOLOGICS will act as the central coordinating agency for the entire mRNA vaccine development process. To achieve its objectives, the company has assembled a consortium of specialized institutions, each contributing unique expertise to the project. This collaborative approach aims to streamline the development pipeline, from initial vaccine candidate design to large-scale production and rigorous clinical testing.

Key Partnerships Drive Innovation

The consortium assembled by EU BIOLOGICS includes several key players in the South korean biotechnology landscape:

• SML Biopharm: Responsible for providing vaccine candidate materials and the crucial MRNA-LNP (lipid nanoparticle) platform.
• Inventage Lab: Tasked with developing efficient and scalable MRNA-LNP production processes.
• Korea Biotechnology Research Institute & Seoul National University: jointly conducting efficacy testing to ensure the vaccines are safe and effective.

This strategic alignment of resources and expertise is expected to accelerate the development and deployment of mRNA vaccines within South Korea.

expanding Vaccine Capabilities: Beyond Protein Subunits

EU BIOLOGICS has a proven track record in developing protein subunit vaccines. This new project represents a strategic expansion of their capabilities, allowing them to leverage the advantages of mRNA technology and diversify their vaccine portfolio. The company anticipates that this initiative will not only strengthen its domestic market position but also enhance its competitiveness in the global vaccine market.

According to a representative from EU BIOLOGICS,This government task selection will go beyond the development of technology,but it will be an important electricity that preoccupies the global next -generation platform called MRNA vaccine and contributes to securing vaccine’s vaccine. The company plans to enter Phase 2 clinical trials before the end of the year, aiming to establish itself as a key player in the global infectious disease response system.

Significant Financial Backing for Ambitious Goals

The KCDC has selected a total of four projects for funding, with the EU BIOLOGICS initiative being one of the recipients.The overall investment in these projects amounts to ₩505.2 billion (approximately $385 million USD). This substantial financial commitment will support the entire development process, from preclinical studies to Phase 3 clinical trials, with the ultimate goal of securing approval for domestically produced mRNA vaccines by 2028. This investment underscores South Korea’s commitment to vaccine independence and its proactive approach to pandemic preparedness.